Status:
APPROVED_FOR_MARKETING
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.
Exclusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03763604
Last Update
December 16 2024
Active Locations (160)
Enter a location and click search to find clinical trials sorted by distance.
1
Liverpool Hospital
Liverpool, New South Wales, Australia, 2170
2
North West Cancer Centre
North Tamworth, New South Wales, Australia, 2340
3
St Vincent's Hospital Sydney
Sydney, New South Wales, Australia, 2010
4
Mater Hospital Sydney
Sydney, New South Wales, Australia, 2060